{"doi":"10.3389/fnmol.2025.1586940","title":"Editorial: Mechanisms of cholinergic transmission in motivation and cognition","abstract":"For this research topic, we have selected 6 original research and review articles exploring the molecular mechanisms of cholinergic transmission in motivation, reward, and reinforcement learning. Including, novel studies on the role of distinct receptor populations and circuitry relevant for attention, reward and motivation (Fritz et al., 2025;Braunscheidel et al., 2024;Kim et al., 2024;Berezovskaia et al., 2024), as well as two reviews of the most relevant studies on cholinergic circuits and striatal cholinergic interneurons (Ratna and Francis, 2025;Runyon et al., 2024).All main cholinergic brain systems have been linked to reward related computations (Ruan et al., 2022). Cholinergic input to the motivation-associated mesolimbic dopamine system arises from distinct neural populations, including projections from two brainstem nuclei, the laterodorsal tegmental nucleus and the pedunculopontine nucleus (PPN), as well as a small population of interneurons in the striatum, comprising 1-2% of all striatal neurons (Dautan et al., 2014;Oakman et al., 1995). Acetylcholine exerts its actions through two receptor families, which originate from distinct genes and are functionally classified by their pharmacological ligand selectivity: Nicotinic and muscarinic acetylcholine receptors. Nicotinic acetylcholine receptors are fast-acting ligand-gated ion channels that facilitate cation influx upon acetylcholine binding, while Muscarinic receptors are slow-acting G-protein coupled receptors, mediating modulatory effects on target neurons (Tobin, 2024;Mihailescu & Drucker-Colin, 2000). In the mammalian central nervous system (CNS), restrictive or selective expression of these receptors in different brain regions dictate their function (Ahmed et al., 2019). The most widely expressed nicotinic receptor subtypes are the α7 homomeric and α4β2 heteromeric nAChRs (Hendrickson et al., 2013); while the muscarinic acetylcholine receptors consist of five subtypes (M1-M5), which all are widely expressed throughout the CNS (Tobin, 2024).For decades, the muscarinic receptor family has been the focus of drug development for treating neuropathology, despite the important role of nicotinic receptors in cognitive and reward functions (Tobin, 2024). In this topic, Braunscheidel and colleagues explored a novel positive allosteric modulator of α4β2 nicotinic receptors, SR9883, for general reward and nicotine reinforced behaviors. They found significant effects on nicotine reward suggesting that SR9883 may hold promise as a novel treatment of tobacco use disorder (Braunscheidel et al., 2025).In the research article, 'Nicotinic α7 receptors on cholinergic neurons in the striatum mediate cocaine reinforcement, but not food reward', Fritz and colleagues uncovered a new role for nicotinic α7 receptors on striatal cholinergic interneurons selective in regulating cocaine seeking and reward, but not natural food reward. These findings suggest that acetylcholine signaling through nicotinic α7 receptors regulate drug selective behaviors, linking nicotinic receptor signaling not only to nicotine reward but also to psychostimulant addiction (Fritz et al., 2025).Striatal cholinergic interneurons (CINs) are rare but exert widespread influence on striatal output by regulating dopamine and glutamate signaling (Cox and Witten, 2019;Picciotto et al., 2012). These interneurons exhibit tonic firing but can generate phasic responses to salient stimuli, contributing to processes such as learning, plasticity, and motor control (Zhang and Cragg 2017). In the review article "Extrinsic and Intrinsic Control of Striatal Cholinergic Interneuron Activity," Ratna and Francis explore the role of CINs, providing an overview of significant findings on their activity. They focus on intrinsic factors and neuromodulators that govern phasic CIN responses involved in learning and plasticity (Ratna and Francis, 2025).Acetylcholine exerts neuromodulatory actions through muscarinic ","journal":"Frontiers in Molecular Neuroscience","year":2025,"id":557446,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9108,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":417438,"name":"Anna M. Klawonn","orcid":"0000-0002-0272-6951","position":1,"is_corresponding":false},{"id":982121,"name":"T. Chase Francis","orcid":"0000-0001-6396-2897","position":0,"is_corresponding":true}],"reference_count":18,"raw_metadata":null,"created_at":"2026-07-19T02:55:17.435961Z","pmid":"40206189","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}